ATHX
Athersys Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.
Market Cap: 2.21 Million
Primary Exchange: NASDAQ
Website: http://www.athersys.com/
Shares Outstanding: 22.5 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.2841032048067609
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2727 trading days
From: 2014-01-23 To: 2023-10-17
Lowest Point:
Time Is Brain: Bioxytran's Tissue Oxygenation Therapy May Breathe New Life Into Stroke Victims
via: SeekingAlpha at 2019-06-09 17:30:33:000
Introduction The stroke market is ripe for the taking. Existing treatments are limited, and the unmet medical need is great. In contrast to breakthroughs in many diseases over the past two decades, stroke treatment, especially from drugs, has had minimal improvement for the past 23 ye… read more...
Time Is Brain: Bioxytran's Tissue Oxygenation Therapy May Breathe New Life Into Stroke Victims
via: SeekingAlpha at 2019-06-09 17:30:33:000
Introduction The stroke market is ripe for the taking. Existing treatments are limited, and the unmet medical need is great. In contrast to breakthroughs in many diseases over the past two decades, stroke treatment, especially from drugs, has had minimal improvement for the past 23 ye… read more...
Time Is Brain: Bioxytran's Tissue Oxygenation Therapy May Breathe New Life Into Stroke Victims
via: SeekingAlpha at 2019-06-09 17:30:33:000
Introduction The stroke market is ripe for the taking. Existing treatments are limited, and the unmet medical need is great. In contrast to breakthroughs in many diseases over the past two decades, stroke treatment, especially from drugs, has had minimal improvement for the past 23 ye… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|